Hormone Therapy
Roche breast cancer pill cuts post-surgery recurrence risk by 30% in major trial
Roche; giredestrant; breast cancer; hormone receptor-positive; ER-positive; HER2-negative; oral SERD; endocrine therapy; adjuvant therapy; recurrence risk; phase III lidERA trial; disease-free survival; San Antonio Breast Cancer Symposium
FDA Moves to Remove Black Box Warnings from Menopausal Hormone Therapies
FDA; menopause; hormone therapy; black box warning; HRT; estrogen; progestogen; labeling change; women’s health; menopausal symptoms
Roche’s Oral SERD Achieves Progression-Free Survival Milestone in Pivotal Breast Cancer Trial
Roche; oral SERD; giredestrant; progression-free survival; pivotal study; breast cancer; ER-positive; endocrine therapy; Phase III trial; advanced breast cancer
Pfizer’s IBRANCE Demonstrates Significant Efficacy in HR+, HER2+ Metastatic Breast Cancer
IBRANCE (palbociclib), HR+/ HER2+ metastatic breast cancer, Phase 3 PATINA trial, Progression-free survival (PFS), Standard-of-care therapies, Anti-HER2 therapy, Endocrine therapy
Bayer’s New Drug Shows Promising Phase III Results for Menopause Symptom Relief
Bayer, Phase III results, menopause symptoms, drug, clinical trial, hot flashes, night sweats, hormone therapy
Extended FDA Review Timeline for Ascendis’ Hormone Therapy
Ascendis Pharma, hormone therapy, FDA review, delay, 3 months extension.